Dr. James Orsini, MD
Claim this profileNew Jersey Cancer Care, PA
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
6 reported clinical trials
9 drugs studied
Affiliated Hospitals
Clinical Trials James Orsini, MD is currently running
Lasofoxifene and Abemaciclib vs Fulvestrant and Abemaciclib
for Breast Cancer
The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatment and have locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation. The main question the study aims to answer is: • To compare the efficacy of the combination of lasofoxifene and abemaciclib with that of fulvestrant and abemaciclib Participants will receive either receive 5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day or the combination of fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day.
Recruiting2 awards Phase 312 criteria
RGX-202-01 Combination Therapy
for Colorectal Cancer
This is a Phase 1 study currently evaluating PO administered ompenaclid in combination with FOLFIRI and bevacizumab in patients with advanced (i.e., locally advanced and unresectable, or metastatic) previously treated colorectal adenocarcinoma. The single agent ompenaclid dose escalation stage and the ompenaclid in combination with FOLFIRI and bevacizumab dose escalation stage of the study has been completed; the expansion stage of ompenaclid in combination with FOLFIRI and bevacizumab is ongoing. In April-24 a protocol amendment added a new dose escalation and expansion stage which will evaluate ompenaclid in combination with FOLFOX and bevacizumab in patients with metastatic CRC. It is anticipated that a total of 30 patients will be enrolled in this new dose escalation and expansion stage of the study.
Recruiting1 award Phase 1
More about James Orsini, MD
Clinical Trial Related1 year of experience running clinical trials · Led 6 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments James Orsini, MD has experience with
- VeriStrat® Testing
- Investigational Immunotherapy Tests
- LIQUIK
- RGX-202-01
- FOLFIRI
- Bevacizumab
Breakdown of trials James Orsini, MD has run
Lung Cancer
Non-Small Cell Lung Cancer
Tumors
Breast Cancer
Gastrointestinal Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does James Orsini, MD specialize in?
James Orsini, MD focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved treating patients, or patients who are undergoing treatment.
Is James Orsini, MD currently recruiting for clinical trials?
Yes, James Orsini, MD is currently recruiting for 2 clinical trials in Belleville New Jersey. If you're interested in participating, you should apply.
Are there any treatments that James Orsini, MD has studied deeply?
Yes, James Orsini, MD has studied treatments such as VeriStrat® Testing, Investigational Immunotherapy Tests, LIQUIK.
What is the best way to schedule an appointment with James Orsini, MD?
Apply for one of the trials that James Orsini, MD is conducting.
What is the office address of James Orsini, MD?
The office of James Orsini, MD is located at: New Jersey Cancer Care, PA, Belleville, New Jersey 07042 United States. This is the address for their practice at the New Jersey Cancer Care, PA.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.